Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Companies and Investors Gather in San Francisco for J.P. Morgan Healthcare Conference January 8-11
Posted on January 9th, 2018 by Christy J. Wilson in Pharma R&D
Healthcare companies and investors are flocking to San Francisco from January 8-11 for the 36th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel. In its first incarnation in 1983, the conference was hosted by Hambrecht & Quist (later acquired by Chase, which was later acquired by J.P. Morgan) and had only about 200 attendees gathered to discuss the burgeoning biotech industry. This year, some 9,000 attendees are expected, with over 450 public and private companies giving presentations.
The conference, which bills itself as the “largest and most informative healthcare investment symposium in the industry,” is by invitation only, and J.P. Morgan seems to enjoy preserving an aura of exclusivity around it. Tech titan Bill Gates will be delivering the keynote address on the first day of the conference, with J.P. Morgan Chase CEO Jamie Dimon offering the keynote the following day. Interestingly, on January 10, the conference will be inviting political perspectives to the stage with keynotes by CNN political analyst Paul Begala and Fox News host Tucker Carlson.
The companies that will be presenting at the conference represent all aspects of the healthcare industry, from pharma companies to medical device firms, non-profits and for-profits, and every kind of company ranging from well-known giants to innovative start-ups. Participating companies represent a wide array of specialties and research focuses, with some of the biggest names including Humana, Teva, AbbVie, Gilead Sciences, Allergan, Mylan and Regeneron.
But perhaps most exciting is the opportunity to hear from lesser-known innovators that are doing interesting work in biotechnology and pharmaceutical R&D. For instance, radiation oncology company Accuray Incorporated is focused on tumor treatment solutions; Accelerate Diagnostics is an in vitro diagnostics firm working on solutions to antibiotic resistance; Sangamo Therapeutics is developing genomic therapies; and Clementia Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on treating ultra-rare bone disorders. And those are just a small sampling of the many companies scheduled to present.
If the uninvited are feeling a little left out, some may still find that networking and learning opportunities still abound outside the Westin St. Francis Hotel, if they are willing to look for them. As Global Biodefense puts it, “The event has evolved into the largest annual convergence of biotech innovators and investors, with or without an invitation. The city becomes a hub for strategic meetings and new technology licensing deals, with corporations renting out large hotel blocks, conference and reception spaces for networking opportunities and presentations.”
For those staying home, though, some companies will be webcasting their presentations. Furthermore, J.P. Morgan will provide some blogs and live updates, which can be found on their website.
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Christy J. Wilson
Sr. Director, Pharma and Biotech Segment
Connect on LinkedIn
Follow on Twitter
- How Pharma Can Make the Most of Gene Tech CRISPR
- Pills Have Gone Digital
- Seeking Other Perspectives to Tease Out New Innovations
- As Drug Development Costs Skyrocket, AI Offers Some Hope
- Myelo Therapeutics Takes on Unmet Needs in Cancer